12/15
06:15 am
ostx
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma [Yahoo! Finance]
Medium
Report
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma [Yahoo! Finance]
11/21
07:04 pm
ostx
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25 [Yahoo! Finance]
Low
Report
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25 [Yahoo! Finance]
11/20
08:16 am
ostx
OS Therapies to spin off OS Animal Health into a standalone public company [Seeking Alpha]
Medium
Report
OS Therapies to spin off OS Animal Health into a standalone public company [Seeking Alpha]
11/20
08:00 am
ostx
OS Therapies to Spinoff OS Animal Health into Standalone Public Company [Yahoo! Finance]
Medium
Report
OS Therapies to Spinoff OS Animal Health into Standalone Public Company [Yahoo! Finance]
11/17
06:36 am
ostx
OS Therapies GAAP EPS of -$0.21 misses by $0.08 [Seeking Alpha]
Low
Report
OS Therapies GAAP EPS of -$0.21 misses by $0.08 [Seeking Alpha]
10/10
06:07 am
ostx
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma [Yahoo! Finance]
Medium
Report
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma [Yahoo! Finance]
10/7
12:07 pm
ostx
OS Therapies to Participate in Fall 2025 Conferences and Events [Yahoo! Finance]
Neutral
Report
OS Therapies to Participate in Fall 2025 Conferences and Events [Yahoo! Finance]
9/30
08:04 pm
ostx
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update [Yahoo! Finance]
Low
Report
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update [Yahoo! Finance]
9/30
09:03 am
ostx
OS Therapies (NYSE:OSTX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $20.00 price target on the stock.
Low
Report
OS Therapies (NYSE:OSTX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $20.00 price target on the stock.